海外の治験の状況「1」での検索結果
224件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Empagliflozin as Adjunctive to inSulin thErapy in Type 1 diabetes over 52 weeks (EASE-2)
- Type 1 diabetes mellitus br>MedDRA version: 19.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-04-02
Authorised
- MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
- MedDRA version: 20.0 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan, United Kingdom, United States
- 2013-01-17
Authorised
- Clinical Trial Testing the Safety of Four Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer
- Second Line Gastric or Gastroesophageal Junction Adenocarcinoma MedDRA version: 18.0 Level: PT Classification code 10063916 Term: Metastatic gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, France, Hungary, New Zealand, Poland, Romania, Russian Federation, Slovakia, United Kingdom, United States
- 2015-03-04
Authorised
- Afatinib as second-line therapy for lung cancer with EGFR mutation
- Metastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R) MedDRA version: 17.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 17.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Algeria, Egypt, Malaysia, Philippines, Poland, Romania, Serbia, Thailand, Tunisia
- 2014-07-02
Authorised
- A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host disease
- Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD MedDRA version: 20.1 Level: PT Classification code 10066260 Term: Acute graft versus host disease System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066262 Term: Acute graft versus host disease in skin System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066264 Term: Acute graft versus host disease in intestine System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066263 Term: Acute graft versus host disease in liver System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Austria, Belgium, Canada, Czech Republic, Finland, Greece, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Switzerland, Taiwan, Turkey, United States
- 2017-07-20
Authorised
- Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy
- Metastatic colorectal cancer MedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Bulgaria, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2018-02-12
Authorised
- Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy
- Metastatic colorectal cancer MedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Bulgaria, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Turkey, Ukraine, United Kingdom
- 2018-01-25
Authorised
- A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
- Relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) who have achieved at least partial response (PR) to second-line therapy. MedDRA version: 20.1 Level: LLT Classification code 10008978 Term: Chronic lymphocytic leukemia refractory System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, United Kingdom, United States
- 2008-10-31
Authorised
- Study for Efficacy and Tolerability of Entospletinib in Combination with Corticosteroids as First-Line Therapy in (cGVHD)
- Chronic Graft Versus Host Disease (cGVHD) MedDRA version: 20.0 Level: PT Classification code 10066261 Term: Chronic graft versus host disease System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]
- Australia, Canada, France, Germany, Korea, Republic of, Spain, United Kingdom, United States
- 2016-02-12
Authorised
- Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial Bladder Cancer
- Adult patients (age =18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV (ie, =T4bN0M0 for bladder), and who are chemotherapy-naïve. MedDRA version: 20.0 Level: LLT Classification code 10022880 Term: Invasive bladder cancer stage IV System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2015-11-10